Antibiotic Resistance Kills 35,000 Annually in EU, ECDC Warns 2030 Goals Unlikely

Antibiotic-resistant bacteria kill more than 35,000 people each year in the European Union, a death toll comparable to influenza, tuberculosis and HIV combined, according to a report from the European Centre for Disease Prevention and Control (ECDC) published on Wednesday to mark European Antibiotic Awareness Day.

The report carries a sobering verdict: antibiotic use across the EU fell 5% in 2025 compared with 2019, yet the bloc’s own target calls for a 20% reduction by 2030, according to PÚBLICO. At the current pace, the ECDC judges the 2030 goals unlikely to be met.

One in three microorganisms found in healthcare-associated infections is an important antibiotic-resistant bacterium, which narrows treatment options, the ECDC points out.

“Without effective antibiotics, we could return to the pre-antibiotic era, and it would be difficult, if not impossible, to safely perform organ transplants, cancer chemotherapy, intensive care or other medical procedures,” the ECDC report says.

Antibiotic misuse drives resistance in Europe

  • Taking them for flu or SARS-CoV-2 does nothing and should only be used when there is medical indication.
  • Most antibiotic use — about 90% across the EU — happens in ambulatory settings.
  • Half of the burden of disease attributed to antimicrobial resistance in Europe is due to healthcare-associated infections involving multidrug-resistant bacteria, and half of this burden could be prevented with more effective infection prevention and control measures.

The gap between progress and the 2030 target

Total EU antibiotic consumption in 2025 was 5% below the 2019 baseline; the EU target for 2030 is a 20% cut, according to RTP. The ECDC concludes that without stronger and faster public health action, resistance will continue to compromise public health, leading to harder-to-treat infections, patient-safety challenges and more deaths.

image name
Photo: RTP

Estimated incidence of bloodstream infections from carbapenem-resistant Klebsiella pneumoniae in the European Union and European Economic Area rose 72% between 2019 and 2025, reaching 3.75 cases per 100,000 inhabitants in 2025. Carbapenem-resistant infections from K. pneumoniae and Escherichia coli are associated with high mortality rates in patients. Resistant E. coli infections rose 16.4% between 2019 and 2025, despite the target of reducing those cases by 10% compared to the 2019 baseline value.

Cyprus recorded a 716% increase in K. pneumoniae infections, illustrating how unevenly the burden falls across health systems.

Where the deaths happen

More than 70% of the burden of disease attributed to antimicrobial resistance in Europe stems from healthcare-associated infections involving multidrug-resistant bacteria, for instance when patients are infected during hospital admission. The ECDC estimates half of that burden could be prevented with adequate infection prevention and control measures.

https://img.iol.pt/preset/635c0aae0cf2ea367d55aab0/og/cnn
Photo: CNN Portugal

Multidrug-resistant strains severely limit treatment options.

Portugal’s numbers against Europe’s

Total antibiotic consumption there decreased from 19.3 defined daily doses per 1,000 inhabitants per day (DHD) in 2019 to 18.3 in 2025. Portugal lowered its antibiotic consumption by 5.2% between 2019 and 2025, approaching the target of a 9% reduction by 2030, though Infarmed notes in its “Deep Dive” monthly publication that Portugal will still need to reduce by approximately another 4 percentage points to reach the national target of 17.6 DHD by 2030.

Europa arrisca regressar à era pré-antibióticos, alerta ECDC
Photo: euronews
Indicator 2019 2025 Target
EU antibiotic consumption vs 2019 baseline −5% −20% by 2030
Portugal consumption (DHD) 19.3 18.3 17.6 by 2030
Resistant E. coli bloodstream infections (EU) baseline +16.4% −10% by 2030
Carbapenem-resistant K. pneumoniae bloodstream infections (EU) baseline +72% reduction

Data from Infarmed show that the decrease in antibiotic consumption dropped in 2025 after four years of increases, resulting mainly from reduced consumption in the community, while hospital consumption remained stable.

The three entities are promoting a meeting in Lisbon on Wednesday, “Preventing Infections, Preserving Antimicrobials – From evidence to implementation: priorities up to 2030,” including the signing of a protocol under the DRIVE-AMS project between the DGS, ULS São João, IPO do Porto, and ULS Tâmega e Sousa to reinforce support programs for prescription and appropriate use of antimicrobials.

The ECDC warns that antimicrobial resistance will continue to increasingly compromise public health, leading to an increased number of infections by antimicrobial-resistant bacteria that will be harder to treat, as well as greater challenges for patient safety and an increase in deaths related to antimicrobial resistance.

The Lisbon meeting and the DRIVE-AMS protocol signed on Wednesday are immediate steps on the Portuguese side toward addressing the prevention of infections and appropriate use of antimicrobials.

References

Disclaimer: This article is journalistic coverage of an official report and is not medical advice. Consult a qualified healthcare professional for guidance on any infection or treatment.

Photo of author

Health Desk

Health Desk at Archyde.

Ahmed Helmy, Mona Zaki Celebrate Shared Birthday; Actor Recalls Jealousy Over Hazem Emam

China Releases Revised Engineering Competence Standard to Support International Mutual Recognition